your market intelligence analyst
Search Results
Edit Save
1,671 results
Lancet 05/28/2020 19:12
2019 was The Lancet's Year for Nutrition. Highlights included reports from the EAT-Lancet Commission1 and The Global Syndemic Commission,2 both emphasising that global trade systems must be transformed to ensure healthy and sustainable diets. But what developments can be expected following these reports? We might get an indication by considering what has happened since The Lancet's 2009 Trade and Health Series. This Series criticised the trade agreements of the World Trade Organization (WTO) for being detrimental to global health, among other things, by facilitating unhealthy diets.
Lancet 05/28/2020 19:12
We read with interest the Correspondence by Zsuzsanna Varga and colleagues1 on the possible infection of endothelial cells by SARS-CoV-2 using electron microscopic (EM) images as evidence. However, we believe the EM images in the Correspondence do not show coronavirus particles but instead show cross-sections of the rough endoplasmic reticulum (RER). These spherical structures are surrounded by dark dots, which might have been interpreted as spikes on coronavirus particles but are instead ribosomes.
Lancet 05/28/2020 19:12
Coronavirus disease 2019 (COVID-19) has revealed how strikingly unprepared the world is for a pandemic and how easily viruses spread in our interconnected world. A governance crisis is unfolding alongside the pandemic as health officials around the world compete for access to scarce medical supplies. As governments of African countries, and those in low-income and middle-income countries around the world, seek to avoid potentially catastrophic epidemics and learn from what has worked in other countries, testing and other medical resources are of concern.
Lancet 05/28/2020 19:12
Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020; 395: 1278–91—In this Article, the second instance of obinutuzumab in the title was misspelled and has been corrected. In table 1, the row labelled Chromosome 17p13·1 deletion or mutated TP53 has been corrected to Chromosome 17p13·1 deletion and/or mutated TP53, and data in this row have been updated.
Lancet 05/28/2020 19:12
Indigenous communities worldwide share common features that make them especially vulnerable to the complications of and mortality from COVID-19. They also possess resilient attributes that can be leveraged to promote prevention efforts. How can indigenous communities best mitigate potential devastating effects of COVID-19? In Bolivia, where nearly half of all citizens claim indigenous origins, no specific guidelines have been outlined for indigenous communities inhabiting native communal territories.
Lancet 05/28/2020 19:12
Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019; 394: 1940–48—In this Article, the Declaration of interests have been corrected for Karen S McCoy, Bonnie W Ramsey, Steven M Rowe, and John J Welter. These corrections have been made to the online version as of May 28, 2020.
Lancet 05/28/2020 19:12
Early triple antiviral therapy was safe and superior to lopinavir–ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19. Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted.
Lancet 05/28/2020 19:12
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569–78. In this Article, a sentence has been added to the Acknowledgments as follows: This work was also supported by the China Evergrande Group, Jack Ma Foundation, Sino Biopharmaceutical, Ping An Insurance (Group), and New Sunshine Charity Foundation. In the legend of table 3, “seven-category ordinal scale” has been corrected to “six-category ordinal scale”.
Lancet 05/28/2020 19:12
Gaudinski MR, Coates EE, Novik L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet 2019; 393: 889–98—In figure 2 of this Article, in part C, the group three serum concentration on day 14 should have been 629·32 μg/mL (SD 118·19). This correction has been made to the online version as of May 28, 2020.
Lancet 05/28/2020 19:12
We provide policy makers, researchers, and the public a simple model and an online tool for understanding excess mortality over 1 year from the COVID-19 pandemic, based on age, sex, and underlying condition-specific estimates. These results signal the need for sustained stringent suppression measures as well as sustained efforts to target those at highest risk because of underlying conditions with a range of preventive interventions. Countries should assess the overall (direct and indirect) effects of the pandemic on excess mortality.
Lancet 05/28/2020 19:12
McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020; 395: 1496–505—The appendix of this Article has been corrected as of May 28, 2020.
Lancet 05/21/2020 19:12
Clark H, Coll-Seck A M, Banerjee A, et al. A future for the world's children? A WHO-UNICEF–Lancet Commission. Lancet 2020; 395: 605–58—In this Commission, the affiliation details for S Peterson, D B Hipgrave, and J Requejo were incorrect and have been changed to “UNICEF Headquarters, Programme Division, Health Section (S Peterson MD, D B Hipgrave PhD), and Division of Data, Analysis, Planning and Monitoring, Data and Analytics Section, New York, USA (J Requejo PhD)”. Affiliation details for ZA Bhutta (Center of Excellence in Women and Child Health, the Aga Khan University, Karachi, Pakistan) have been added.
Lancet 05/21/2020 19:12
131 million women give birth annually. This population is particularly vulnerable to emerging infectious pathogens due to alterations in immune, respiratory, and cardiovascular physiology that occur during pregnancy. Recent outbreaks of severe acute respiratory syndrome, Middle East respiratory syndrome, influenza H1N1, Ebola virus disease, and Zika virus disease exposed high rates of maternal morbidity and mortality, fetal loss, and fetal harm. Early data regarding pregnancy outcomes in COVID-19 are reassuring: maternal outcomes are similar to non-pregnant adults, and vertical transmission and neonatal infection are rare.

Chemicals - Agricultural

Chemicals - Industrial

Business Issues

Companies - Public

Companies - Venture Funded

Commodity Prices

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Political Entities


Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications